| Title |
The Efficacy of Hypericum perforatum (St John’s Wort) for the Treatment of Premenstrual Syndrome
|
|---|---|
| Published in |
CNS Drugs, August 2012
|
| DOI | 10.2165/11530120-000000000-00000 |
| Pubmed ID | |
| Authors |
Sarah Canning, Mitch Waterman, Nic Orsi, Julie Ayres, Nigel Simpson, Louise Dye |
| Abstract |
Premenstrual syndrome (PMS) is a common condition. Some of the most widely prescribed medications are selective serotonin reuptake inhibitors (SSRIs), based on the hypothesized role of serotonin in the production of PMS symptoms. PMS sufferers, especially those experiencing mild to moderate symptoms, are often reluctant to take this form of medication and instead buy over-the-counter preparations to treat their symptoms, for which the evidence base with regard to efficacy is limited. Hypericum perforatum (St John's wort) influences the serotonergic system. As such, this widely available herbal remedy deserves attention as a PMS treatment. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 33% |
| Netherlands | 1 | 33% |
| New Zealand | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 2 | 67% |
| Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 197 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Canada | 1 | <1% |
| Australia | 1 | <1% |
| Unknown | 194 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 47 | 24% |
| Student > Master | 28 | 14% |
| Student > Ph. D. Student | 18 | 9% |
| Student > Doctoral Student | 14 | 7% |
| Researcher | 11 | 6% |
| Other | 30 | 15% |
| Unknown | 49 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 48 | 24% |
| Psychology | 31 | 16% |
| Nursing and Health Professions | 14 | 7% |
| Agricultural and Biological Sciences | 9 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 3% |
| Other | 34 | 17% |
| Unknown | 55 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 June 2022.
All research outputs
#2,165,251
of 25,374,917 outputs
Outputs from CNS Drugs
#162
of 1,388 outputs
Outputs of similar age
#13,995
of 187,955 outputs
Outputs of similar age from CNS Drugs
#56
of 541 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,388 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,955 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 541 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.